Recent BEAM News
- Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) • GlobeNewswire Inc. • 03/26/2024 10:30:00 AM
- Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences • GlobeNewswire Inc. • 02/28/2024 11:30:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/27/2024 12:40:17 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/27/2024 12:22:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 11:43:02 AM
- Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones • GlobeNewswire Inc. • 02/27/2024 11:30:00 AM
- Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference • GlobeNewswire Inc. • 02/05/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:05:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:05:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:05:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:05:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:05:06 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/31/2024 09:47:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 11:55:18 AM
- Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones • GlobeNewswire Inc. • 01/08/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 09:30:09 PM
- Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/02/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/14/2023 09:05:55 PM
- Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors • GlobeNewswire Inc. • 12/14/2023 11:30:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/20/2023 09:20:20 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/08/2023 12:30:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2023 12:00:08 PM
- Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/08/2023 11:30:00 AM
- Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference • GlobeNewswire Inc. • 11/08/2023 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/01/2023 08:30:07 PM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM